Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 152


Monocyte chemoattractant protein-2 (CC chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1 via CC chemokine receptor 5.

Yang OO, Garcia-Zepeda EA, Walker BD, Luster AD.

J Infect Dis. 2002 Apr 15;185(8):1174-8. Epub 2002 Apr 1.


Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication.

Gong W, Howard OM, Turpin JA, Grimm MC, Ueda H, Gray PW, Raport CJ, Oppenheim JJ, Wang JM.

J Biol Chem. 1998 Feb 20;273(8):4289-92.


The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.

Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, Bukrinsky M.

J Exp Med. 1999 Sep 6;190(5):597-605.


Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.

Münch J, Ständker L, Pöhlmann S, Baribaud F, Papkalla A, Rosorius O, Stauber R, Sass G, Heveker N, Adermann K, Escher S, Klüver E, Doms RW, Forssmann WG, Kirchhoff F.

Antimicrob Agents Chemother. 2002 Apr;46(4):982-90.


Limited expression of R5-tropic HIV-1 in CCR5-positive type 1-polarized T cells explained by their ability to produce RANTES, MIP-1alpha, and MIP-1beta.

Annunziato F, Galli G, Nappi F, Cosmi L, Manetti R, Maggi E, Ensoli B, Romagnani S.

Blood. 2000 Feb 15;95(4):1167-74.


CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells.

Ruffing N, Sullivan N, Sharmeen L, Sodroski J, Wu L.

Cell Immunol. 1998 Nov 1;189(2):160-8.


CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.

Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, Vassart G, Doms RW, Parmentier M.

Blood. 1999 Sep 15;94(6):1899-905.


Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.

Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, Monaco J, Ehler L, Mizell S, Jackson R, Li Y, Romano JW, Fauci AS.

J Clin Invest. 1998 Jul 1;102(1):223-31.


Inhibition of CCR5 expression by IL-12 through induction of beta-chemokines in human T lymphocytes.

Wang J, Guan E, Roderiquez G, Norcross MA.

J Immunol. 1999 Dec 1;163(11):5763-9.


The limited infectability by R5 HIV of CD34(+) cells from thymus, cord, and peripheral blood and bone marrow is explained by their ability to produce beta-chemokines.

Majka M, Rozmyslowicz T, Ratajczak J, Dobrowsky A, Pietrzkowski Z, Gaulton GN, Janowska-Wieczorek A, Ratajczak MZ.

Exp Hematol. 2000 Dec;28(12):1334-42.


IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.

Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F.

J Leukoc Biol. 2002 Oct;72(4):735-42.


Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1.

Vicenzi E, Alfano M, Ghezzi S, Gatti A, Veglia F, Lazzarin A, Sozzani S, Mantovani A, Poli G.

J Leukoc Biol. 2000 Sep;68(3):405-12.


Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).

Elliott MB, Tebbey PW, Pryharski KS, Scheuer CA, Laughlin TS, Hancock GE.

J Med Virol. 2004 Jun;73(2):300-8.


Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5).

Ruff MR, Melendez-Guerrero LM, Yang QE, Ho WZ, Mikovits JW, Pert CB, Ruscetti FA.

Antiviral Res. 2001 Oct;52(1):63-75.


Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells.

Vyakarnam A, Eyeson J, Teo I, Zuckerman M, Babaahmady K, Schuitemaker H, Shaunak S, Rostron T, Rowland-Jones S, Simmons G, Clapham P.

AIDS. 2001 Sep 7;15(13):1613-26.


The synthetic peptide WKYMVm attenuates the function of the chemokine receptors CCR5 and CXCR4 through activation of formyl peptide receptor-like 1.

Li BQ, Wetzel MA, Mikovits JA, Henderson EE, Rogers TJ, Gong W, Le Y, Ruscetti FW, Wang JM.

Blood. 2001 May 15;97(10):2941-7.


HIV co-receptors as targets for antiviral therapy.

Schols D.

Curr Top Med Chem. 2004;4(9):883-93. Review.


Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.

Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.

J Virol. 2004 Aug;78(16):8654-62.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk